[TLOG] TetraLogic Pharmaceuticals Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.03 Change: 0 (1.33%)
Ext. hours: Change: 0 (0%)

chart TLOG

Refresh chart

Strongest Trends Summary For TLOG

TLOG is in the long-term down -100% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: TetraLogic Pharmaceuticals Corporation operates as a clinical-stage biopharmaceutical company in the United States. The company focuses on discovering and developing novel small molecule therapeutics that mimic novel second mitochondrial activator of caspases to cause or enable abnormal cells, which are resistant to the body?s immune system to self-destruct. Its clinical-stage product candidate, Birinapant, is in Phase I and Phase II oncology clinical trials for multiple solid tumors and hematological malignancies. The company?s clinical and pre-clinical programs comprise an ongoing Phase I/II clinical trial of birinapant as a single agent in various blood cancers; a Phase I/II completed clinical trial of birinapant administered with irinotecan in colorectal cancer; and a Phase I/II clinical trial of birinapant administered with conatumumab in ovarian cancer, as well as an intention to start Phase I clinical trial in hepatitis B virus. It has collaboration with Amgen, Inc. for exploring the combination of bir

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-39.24% ROE-176.91% ROI-50.03%
Current Ratio6.96 Quick Ratio Long Term Debt/Equity0.72 Debt Ratio0.28
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-800 K Cash From Investing Activities11.91 M Cash From Operating Activities-7.24 M Gross Profit
Net Profit-12.68 M Operating Profit-10.63 M Total Assets110.35 M Total Current Assets48.1 M
Total Current Liabilities6.91 M Total Debt27.56 M Total Liabilities85.88 M Total Revenue
Technical Data
High 52 week0.06 Low 52 week0.02 Last close0.02 Last change-10.45%
RSI46.7 Average true range Beta1.17 Volume104.24 K
Simple moving average 20 days-7.6% Simple moving average 50 days-17.76% Simple moving average 200 days-23.52%
Performance Data
Performance Week1.03% Performance Month-11.26% Performance Quart-10.45% Performance Half-14.72%
Performance Year10.06% Performance Year-to-date-1.99% Volatility daily8.54% Volatility weekly19.09%
Volatility monthly39.12% Volatility yearly135.52% Relative Volume84.1% Average Volume14.7 K
New High New Low

News

2016-12-30 08:25:14 | TetraLogic completes $12M asset sale to Swedish drug developer

2016-12-30 07:45:06 | TetraLogic complete $12M asset sale to Swedish drug developer

2016-12-29 10:30:00 | TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir AB

2016-11-22 08:27:07 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Unregistered Sale of Equity Securities, Material Modification to

2016-11-14 17:07:17 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements

2016-11-08 13:04:13 | TETRALOGIC PHARMACEUTICALS CORP Financials

2016-11-04 12:20:12 | $12M deal: Malvern biopharm firm sells assets to Swedish drug developer

2016-11-03 17:29:22 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Costs Associated with

2016-11-02 18:07:15 | TetraLogic Announces Agreements to Sell SMAC mimetic and HDAC inhibitor assets to Medivir and to Restructure its Convertible Senior Notes and Delisting of Common Stock

2016-11-02 16:51:00 | Medivir Strengthens Its Clinical Pipeline by Entering into Agreement to Acquire a Portfolio of Clinical Stage Oncology Programs

2016-11-02 16:45:19 | Medivir strengthens its clinical pipeline by entering into agreement to acquire a portfolio of clinical stage oncology programs

2016-11-02 16:30:00 | TetraLogic Announces Agreements to Sell SMAC mimetic and HDAC inhibitor assets to Medivir and to Restructure its Convertible Senior Notes and Delisting of Common Stock

2016-10-19 16:07:21 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul

2016-09-06 16:06:14 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul

2016-09-01 16:03:40 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul

2016-08-11 13:24:34 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report

2016-07-22 16:19:59 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers

2016-07-20 16:21:25 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul

2016-06-15 16:06:50 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders

2016-05-04 13:32:39 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report

2016-04-26 08:26:00 | 4 Trending Small Cap Stocks That You Need To Watch Today

2016-04-25 12:44:00 | Penny Stocks To Watch: Four Top Small Cap Stocks on Monday April 25

2016-04-15 12:09:00 | Top Penny Stocks: Four Small Cap Stocks You Should Be Watching On April 15th

2016-04-07 16:07:21 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers

2016-03-16 15:31:04 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 10-K, Annual Report

2016-02-26 07:01:48 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul

2016-02-03 13:49:00 | These Biotech Companies are Helping Turn Around the Sector for Major Gains in 2016

2016-02-03 12:37:22 | TETRALOGIC PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers

2016-01-13 09:45:00 | Insider Alert: Here's Why These Small Caps Could Be Ready To Bounceā€¦

2016-01-07 11:12:02 | TetraLogic Pharmaceuticals Announces Data on Lead Clinical Programs

2016-01-07 08:41:15 | Here's Why Tetralogic Pharmaceuticals Is Down 70%

2015-12-31 10:02:00 | LifeSci Capital Initiates Coverage of TetraLogic Pharmaceuticals Corporation

2015-12-31 08:30:50 | Roth Capital's New Buy Rating On TetraLogic: 'SMAC'ing Cancer Around'

2015-11-06 09:52:09 | Odey Asset Management and Clinton Group Discarding Two Low-Priced Stocks, While Whitebox Advisors Goes Long This Biotech

2015-10-07 08:14:00 | Pharmaceutical Sector Due Diligence Report - Searching for Opportunities Among the Bruised Small Cap Market